13 August 2018
Visiongain has launched a new pharma report Forecasts By Product (Spinal Cord Stimulators, Deep Brain Stimulators, Vagus Nerve Stimulators, Sacral Nerve Stimulators, Cortical Stimulators and Others), By Application (Epilepsy, Pain Management, Hearing Loss, Incontinence, Gastroparesis, Parkinson’s Disease and Others) and Geography
The prevalence rates of the spectrum of neurological disorders have been increased significantly in many countries across the globe. According to the Federal Interagency Forum on Aging-Related Statistics, around 35.8% of those 85 or older have moderate or severe memory impairment. Persons 85 years and older are the fastest growing segment of the population. In the U.S., around 1.2 million people aged 18 years and older who are diagnosed annually with adult onset brain disease/disorders.
Neurostimulation is an advanced treatment which helps to reduce certain types of chronic pain or manage neurological conditions. Neurostimulation devices are surgically implanted in the body of the patient and function through thin wires or leads which help them find relief from chronic pain or other neurological conditions.
The lead Visiongain report analyst for this report commented “The risk of chronic and infectious diseases increases with age. Among the geriatric population, the chronic diseases prevalence rate is 64/1,000 persons. The trend of the current rapid rise in elderly population is observed in many regions globally, which is expected to increase the number of patients suffering from chronic diseases such as epilepsy, consequently increasing the demand for various medical devices required for various procedures.”
Thus, with increasing incidence of neurological diseases, the demand for neurostimulation devices is expected to increase significantly in the next few years.
Leading companies who are active in the Neurostimulation market and are featured in the report include Advanced Bionics, Boston Scientific Corporation, Cochlear ltd, Cyberonics, Medtronic Neuronetics Inc, Nervo Corp., Cogentic Medical Inc, St Jude Medical and NDI Medical.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The Global Genome Editing Technologies market is estimated to be valued at US$ 4,225.48 million in 2022. The market is projected to reach a market value of US$ 18,570.41 million by 2032. We predict strong revenue growth through to 2032.
02 August 2022
The global synthetic biology market was valued at US$13.8 billion in 2021 and is projected to grow at a CAGR of 25.52% during the forecast period 2022-2032.
27 July 2022
The global biosimilar monoclonal antibodies market was valued at US$4,087 million in 2021 and is projected to grow at a CAGR of 23.5% during the forecast period 2022-2032.
25 July 2022
The global drug discovery services market is anticipated to be valued at US$14.17 billion in 2022 and is projected to grow at a CAGR of 15.17% during the forecast period 2022-2032.